Howard M. Stern

Medicine · Health Sciences

50h-index11.8kcitations189works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(38), PI3K/AKT/mTOR signaling in cancer(33), Monoclonal and Polyclonal Antibodies Research(32), Cancer Genomics and Diagnostics(21), Ferroptosis and cancer prognosis(18)

Publications189 total

Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
2023Open Access
Data from PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
2023Open Access
Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
2023Open Access
Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Data from PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
2023Open Access
Supplementary Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
2023Open Access
Data from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Supplementary Methods, Figures 1-4 from PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
2023Open Access
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Supplementary Figures S1-S4 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Supplementary Methods, Figures 1-4 from PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
2023Open Access
Supplementary Table S1 from Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
2023Open Access
Data from Oncogenic Activating Mutations Are Associated with Local Copy Gain
2023Open Access
Supplementary Methods, Figures 1-9, Tables 1-4 from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
2023Open Access
Data from DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non–Small Cell Lung Cancer
2023Open Access
Supplemental Figure 4b from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
2023Open Access
Supplemental Figure 3b from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
2023Open Access
Data from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
2023Open Access
Supplemental Figure 3b from PTEN Loss Is Associated with Worse Outcome in <i>HER2</i>-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Somasekar Seshagiri(17), Zora Modrušan(15), Jeremy Stinson(11), Frédéric J. de Sauvage(11), Peter M. Haverty(10), Leonard I. Zon(8), Zemin Zhang(7), Vasantharajan Janakiraman(6), Thomas D. Wu(6), Richard Bourgon(6), David Stokoe(6), Klaus P. Hoeflich(6), Noelyn M. Kljavin(6), Lukas C. Amler(6), Eric Stawiski(5), David S. Shames(5), Subhra Chaudhuri(5), Suchit Jhunjhunwala(5), Mark R. Lackner(5), Carol O’Brien(5)